A Phase 4 interventional study of Tenofovir DF and DEXA Scan in Hepatitis B, sponsored by Gilead Sciences. Terminated at 11 sites in 7 countries. Open to participants aged 12 Years to 15 Years. Per ClinicalTrials.gov, last updated 2019-05-20.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing tenofovir in Hepatitis B — none open to participants now, 4 under way, 2 of them phase 3. Tenofovir · Hepatitis B.
Among the 41 studies testing tenofovir in Hepatitis B, this one is the 35th largest by enrollment, is one of 6 that started in 2015, is one of 14 in phase 4, and was the 23rd registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →None of the 41 studies testing tenofovir in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 12 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 11 · Phase 4 14
First in 2004; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 100 across the 41 interventional studies. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 41 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
24 studies in Hepatitis B by Gilead Sciences: none open now, none under way, none of them phase 3. Of 24 finished, 12 (50%) have results posted.
Among the 24 studies in Hepatitis B by Gilead Sciences, this one is the 16th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 4, and was the 24th registered.
Gilead Sciences’s Hepatitis B studies by the year they started, since 2002.
1 of the studies testing tenofovir in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05403047ANRS, Emerging Infectious DiseasesEfficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing tenofovir in Hepatitis B, from their registry updates:
Among Gilead Sciences’s 24 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to characterize the long term (ie, 96 weeks of follow up) bone safety profile of open-label tenofovir disoproxil fumarate (tenofovir DF) treatment in CHB-infected adolescents. This includes prospectively evaluating and comparing the bone mineral density (BMD) change between CHB-infected adolescents 12 to \< 18 years of age treated with tenofovir DF in European treatment centers who are assigned to one of two schedules for renal and bone laboratory monitoring and BMD measurement.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
Drug: Tenofovir DF · Radiation: DEXA Scan
Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
Drug: Tenofovir DF · Radiation: DEXA Scan
300 mg tablet administered orally once daily for up to 96 weeks
Also known as: Viread®
Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96
Time frame: Baseline to Week 96
Participants were enrolled at study sites in Europe. The first participant was screened on 03 July 2015. The last study visit occurred on 11 April 2018. The study did not achieve targeted enrollment as it was prematurely terminated by the Pharmacovigilance Risk Assessment Committee (PRAC).
| Milestone | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring |
|---|---|---|
| Started | 15 | 15 |
| Completed | 2 | 2 |
| Not completed | 13 | 13 |
| Withdrew: Study terminated by sponsor | 13 | 12 |
| Withdrew: Pregnancy | 0 | 1 |
| percentage of participants | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring |
|---|---|---|
| Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96 | 6.7 | 0 |
Collected over Up to 96 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir DF + Increased Bone/Renal Monitoring | 0/15 (0%) | 1/15 (6.7%) | 10/15 (66.7%) |
| Tenofovir DF + Prespecified Bone Monitoring | 0/15 (0%) | 2/15 (13.3%) | 10/15 (66.7%) |
| Event | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring |
|---|---|---|
| CalcinosisGeneral disorders | 1/15 | 0/15 |
| MalaiseGeneral disorders | 0/15 | 1/15 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/15 | 1/15 |
| Event | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring |
|---|---|---|
| Abdominal painGastrointestinal disorders | 1/15 | 2/15 |
| VomitingGastrointestinal disorders | 2/15 | 0/15 |
| PyrexiaGeneral disorders | 2/15 | 0/15 |
| NasopharyngitisInfections and infestations | 2/15 | 0/15 |
| Bone density decreasedInvestigations | 0/15 | 2/15 |
| Vitamin D decreasedInvestigations | 2/15 | 2/15 |
| HeadacheNervous system disorders | 0/15 | 2/15 |
| Abdominal pain lowerGastrointestinal disorders | 0/15 | 1/15 |
| Abdominal pain upperGastrointestinal disorders | 0/15 | 1/15 |
| Anal fissureGastrointestinal disorders | 1/15 | 0/15 |
Safety Analysis Set included participants who were randomized into the study and received at least one dose of tenofovir DF.
| Age, Continuous(years) | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring | Total |
|---|---|---|---|
| Mean | 14 ± 1.4 | 14 ± 1.5 | 14 ± 1.4 |
| Sex: Female, Male(Participants) | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring | Total |
|---|---|---|---|
| Female | 5 | 5 | 10 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 12 | 25 |
| Not Hispanic or Latino | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring | Total |
|---|---|---|---|
| Asian | 2 | 5 | 7 |
| Black or African American | 5 | 5 | 10 |
| White | 7 | 4 | 11 |
| Other | 1 | 1 | 2 |
| Region of Enrollment(participants) | Tenofovir DF + Increased Bone/Renal Monitoring | Tenofovir DF + Prespecified Bone Monitoring | Total |
|---|---|---|---|
| Greece | 1 | 1 | 2 |
| Romania | 4 | 4 | 8 |
| Belgium | 2 | 2 | 4 |
| Italy | 1 | 0 | 1 |
| United Kingdom | 2 | 4 | 6 |
| France | 2 | 1 | 3 |
| Spain | 3 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Feb 2018, 31 months.
Results were first posted in May 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir